Information de reference pour ce titreAccession Number: | 00003571-200104000-00028.
|
Author: | Pedram, Ali; Razandi, Mahnaz; Levin, Ellis R
|
Institution: | Division of Endocrinology, Veterans Affairs Medical Center, Long Beach, California 90822; and Departments of Medicine (A.P., M.R., E.R.L.) and Pharmacology (E.R.L.), University of California, Irvine, California 92717
|
Title: | |
Source: | Endocrinology. 142(4):1578-1586, April 2001.
|
Abstract: | Vascular endothelial cell growth factor (VEGF) is essential for angiogenesis. Atrial natriuretic peptide (ANP) inhibits the production of VEGF, but whether this important vascular peptide also inter- rupts VEGF signaling to angiogenesis is unknown. In cultured bovine aortic endothelial cells, VEGF significantly stimulated extracellular signal-regulated protein kinase activity and phosphorylation, which was inhibited 60% by coincubation with ANP or a natriuretic peptide clearance receptor specific ligand (NPRC), C-type NAP-(4-23) [C-ANP-(4-23)]. VEGF also stimulated c-Jun N-terminal kinase (JNK) and p38 activities/phosphorylation that were prevented by the two natriuretic peptides (NP). A specific NP guanylate cyclase (GC) receptor antagonist, HS-142-1, blocked the actions of ANP [but not those of C-ANP-(4-23)], supporting the involvement of both GC and NPRC receptors. VEGF and expression of constituitively active JNK each stimulated the synthesis of cyclin D1 and increased the activity of the cyclin-dependent kinase-4, which was inhibited 55% by ANP. VEGF induced endothelial cell proliferation and migration, which was significantly blocked by NP or by expressing a dominant negative JNK-1. VEGF stimulated human microvascular endothelial cells to form capillary tubes, which was significantly inhibited by expressing dominant negative JNK-1 and by NP. Therefore, VEGF induction of critical steps in angiogenesis is enhanced through JNK activation. The actions are significantly prevented by NP, which act through both the NPRC and GC receptors to block growth factor signaling. Thus, NP are candidate antiangiogenesis factors that inhibit both the synthesis and function of VEGF.
Copyright (C) 2001 by The Endocrine Society
|
References: | 1. Ferrara N 1993 Vascular endothelial cell growth factor. Trends Cardiovasc Med 3:244-250
2. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N 1993 Inhibition of vascular endothelial cell growth factor-induced angiogenesis suppresses tumor growth in vivo. Science 362:841-844
3. Millauer BS, Wizigmann-Voos H, Schnurch R, Martinez NPH, Moeller W, Risau A, Ullrich A 1993 High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72:835-846
4. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH 1994 Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial cell growth factor. J Biol Chem 269:26988-26995
5. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M 1998 Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92:735-745
6. Guo D, Jia Q, Song H-Y, Warren RS, Donner DB 1995 Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. J Biol Chem 270:6729-6733
7. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu X-F, Breitman ML, Schuh AC 1995 Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376:62-70
8. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A 1994 Glioblastoma growth inhibited in vivo by a dominant negative Flk-1 mutant. Nature 367:576-579
9. Murohara T, Horowitz JR, Silver M, Tsurumi Y, Chen D, Sullivan A, Isner JM 1998 Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation 97:99-107
10. Kroll J, Waltenberger J 1997 The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J Biol Chem 272:32521-32527
11. Pedram A, Razandi M, Levin ER 1998 Extracellular regulated kinase/jun kinase cross-talk underlies vascular endothelial cell growth factor-induced endothelial cell proliferation. J Biol Chem 273:26722-26728
12. Levin ER, Gardner DG, Samson WK 1998 Natriuretic peptides. N Engl J Med 339:321-328
13. Chang M-S, Lowe DG, Lewis M, Hellmiss R, Chen E, Goeddel DV 1989 Differential activation by atrial and brain natriuretic peptides of two different receptor guanylate cyclases. Nature 34:68-71
14. Chinkers M, Garbers DL, Chang MS, Lowe DG, Chin H, Goeddel DV, Schultz S 1989 A membrane form of guanylate cyclase is an atrial natriuretic peptide receptor. Nature 338:78-83
15. Maack T, Suzuki M, Almeida FA, Nussenzveig D, Scarborough RM, McEnroe GA, Lewicki JA 1987 Physiological role of silent receptors of atrial natriuretic factor. Science 238:675-678
16. Itoh H, Pratt RE, Dzau VJ 1992 Atrial natriuretic peptide as a novel antigrowth factor of endothelial cells. Hypertension 19:758-761
17. Levin ER, Frank HJL 1991 Natriuretic peptides inhibit astroglial proliferation: mediation by C receptor. Am J Physiol 261:E183-E189
18. Pedram A, Hu R-M, Levin ER 1997 Vasoactive peptides modulate vascular endothelial cell growth factor production and endothelial cell proliferation and invasion. J Biol Chem 272:17097-17103
19. Volpert OV, Ward WF, Lingen MW, Chesler L, Solt DB, Johnson MD, Molteni A, Polverini PJ, Bouck NP 1996 Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 98:671-679
20. Schrey MP, Patel KV, Tezapsidis N 1992 Bombesin and glucocorticoids stimulate human breast cancer cells to produce endothelin, a paracrine mitogen for breast stromal cells. Cancer Res 52:1786-1790
21. Pedram A, Razandi M, Hu R-M, Levin ER 1998 Astrocyte progression through G1-S phase of the cell cycle depends upon multiple protein interactions. J Biol Chem 273:13966-13972
22. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, Nguyen HV, Aiello LM, Ferrara N, King GL 1994 Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480-1487
23. Itoh H, Pratt RE, Dzau VJ 1990 Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth muscle cells. J Clin Invest 86:1690-1697
24. Cao L, Gardner DG 1995 Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts. Hypertension 25:227-234
25. Wu LW, Mayo LD, Dunbar JD, Kessler KM, Baerwald MR, Jaffe EA, Wang D, Warren RS, Donner DB 2000 VRAP is an adaptor protein that binds KDR, a receptor for vascular endothelial cell growth factor. J Biol Chem 275:5096-5103
26. Rousseau S, Houle F, Landry J, Huot J 1997 p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene 15:2169-2177
27. Radisavljevic Z, Avraham H, Avraham S 2000 Vascular endothelial growth factor up-regulates ICAM-1 expression via the phosphatidylinositol 3 OH-kinase/AKT/nitric oxide pathway and modulates migration of brain microvascular endothelial cells. J Biol Chem 275:20770-20774
28. Rousseau S, Houle F, Kotanides H, Witte L, Waltenberger J, Landry J, Huot J 2000 Vascular endothelial growth factor (VEGF)-driven actin-based motility is mediated by VEGFR2 and requires concerted activation of stress-activated protein kinase 2 (SAPK2/p38) and geldanamycin-sensitive phosphorylation of focal adhesion kinase. J Biol Chem 275:10661-10672
29. Kanno S, Oda N, Abe M, Terai Y, Ito M, Shitara K, Tabayashi K, Shibuya M, Sato Y 2000 Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells. Oncogene 19:2138-2146
30. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, Ferrara N 1998 Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 273:30336-30343
31. Tallquist MD, Soriano P, Klinghoffer RA 1999 Growth factor signaling pathways in vascular development. Oncogene 18:7917-7932
32. Assefa Z, Valius M, Vantus T, Agostinis P, Merlevede W, Vandenheede JR 1999 JNK/SAPK activation by platelet-derived growth factor in A431 cells requires both the phospholipase C-[gamma] and the phosphatidylinositol 3-kinase signaling pathways of the receptor. Biochem Biophys Res Commun 261:641-645
33. Timokhina I, Kissel H, Stella G, Besmer P 1998 Kit signaling through PI 3-kinase and Src kinase pathways: an essential role for Rac1 and JNK activation in mast cell proliferation. EMBO J 17:6250-6262
34. Singh S, Lowe DG, Thorpe DS, Rodriguez H, Kuang WJ, Dangott LJ, Chinkers M, Goeddel DV, Garbers DL 1988 Membrane guanylate cyclase is a cell-surface receptor with homology to protein kinases. Nature 334:708-712
35. Morishita Y. Sano T, Kase H, Yamada K, Inagami T, Matsuda Y 1992 HS-142-1, a novel nonpeptide atrial natriureticpeptide (ANP) antagonist, blocks ANP-induced renal responses through a specific interaction with guanylyl cyclase-linked receptors. Eur J Pharmacol 225:203-207
36. Morishita Y, San T, Ando K, Saitoh Y, Kase H, Yamada K, Matsuda Y 1991 Microbial polysaccharide, HS-142-1, competitively and selectively inhibits ANP binding to its guanylyl cyclase-containing receptor. Biochem Biophys Res Commun 176:949-957
37. Kumar R, Cartledge WA, Lincoln TM, Pandey KN 1997 Expression of guanylyl cyclase-A/atrial natriuretic peptide receptor blocks the activation of protein kinase C in vascular smooth muscle cells. Role of cGMP and cGMP-dependent protein kinase Hypertension 29:414-421
38. Wan Y, Huang X-Y 1998 Analysis of the Gs/mitogen-activated protein kinase pathway in mutant S49 cells. J Biol Chem 273:14533-14537
39. Lopez MJ, Garbers DL, Kuhn M 1997 The guanylyl cyclase-deficient mouse defines differential pathways of natriuretic peptide signaling. J Biol Chem 272:23064-23068
40. Matsukawa N, Grzesik WJ, Takahashi N, Pandey KN, Pang S, Yamauchi M, Smithies O 1999 The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system. Proc Natl Acad Sci USA 96:7403-7408
41. Wei CM, Heublein DM, Perrella MA, Lerman A, Rodeheffer RJ, McGregor CG, Edwards WD, Schaff HV, Burnett Jr JC 1993 Natriuretic peptide system in human heart failure. Circulation 88:1004-1009
42. Oliver PM, Fox JE, Kim R, Rockman HA, Kim HS, Reddick RL, Pandey KN, Milgram SL, Smithies O, Maeda N 1997 Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc Natl Acad Sci USA 94:14730-14735
|
Language: | English.
|
Document Type: | Renin-Mineralocorticoids-ANF-ADH.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0013-7227
|
NLM Journal Code: | egz, 0375040
|
Annotation(s) | |
|
|